An interventional study of Placebo and MPRO3 in Colon Neoplasms, sponsored by hy Co., LTD.. Recruiting at 1 site in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by hy Co., LTD. · Not applicable, Interventional, and Prevention
The goal of this clinical trial is to evaluate the effects of MPRO3(probiotics mixture) supplementation on surgical outcomes and gut health in patients undergoing surgery for colon cancer.The main question is whether MPRO3 supplementation before and after surgery can reduce postoperative infectious complications compared with placebo.Participants will take either MPRO3 or a placebo once daily for 13 weeks, from 1 week before surgery to 12 weeks after surgery. Researchers will compare the two groups to assess postoperative infectious complications, other clinical outcomes, and changes in the gut microbiome.
Exclusion Criteria:
Placebo is a matching formulation that does not contain the three probiotic strains included in MPR03.
Dietary Supplement: Placebo
MPR03 is a probiotic formulation containing a mixture of three probiotic strains: Bifidobacterium animalis subsp. lactis HY8002, Lacticaseibacillus paracasei HY2782, and Lactiplantibacillus plantarum HY7712.
Dietary Supplement: MPRO3
Participants will receive one placebo capsule orally once daily after breakfast for 13 weeks.
Participants will receive one MPRO3 capsule orally once daily after breakfast for 13 weeks.
Postoperative Infectious Complications (Infectious complications)
The occurrence of postoperative infectious complications is assessed according to the CDC/NHSN criteria.
Time frame: 4 weeks after surgery, 12 weeks after surgery
Comprehensive Complication Index
Postoperative complications are graded according to the Clavien-Dindo classification and summarized as a Comprehensive Complication Index score ranging from 0 to 100.
Time frame: 4 weeks after surgery, 12 weeks after surgery
Postoperative Length of Hospital Stay (LOS)
Postoperative length of hospital stay is calculated from the date of surgery to hospital discharge based on medical records.
Time frame: 4 weeks after surgery
Inflammation-related Marker 1: Glasgow prognostic score (GPS)
The Glasgow Prognostic Score (GPS) is assessed using inflammatory markers measured in venous blood and is calculated based on serum albumin and high-sensitivity C-reactive protein (HS-CRP) levels. The total score ranges from 0 to 2. A score of 0 is assigned when HS-CRP is ≤10 mg/L and albumin is ≥35 g/L. A score of 1 is assigned when either HS-CRP is \>10 mg/L or albumin is \<35 g/L. A score of 2 is assigned when HS-CRP is \>10 mg/L and albumin is \<35 g/L. Higher scores indicate a worse prognostic status.
Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery
Inflammation-related Markers 2: White Blood Cell (WBC), C-reactive protein (CRP), Neutrophils, lymphocytes, Monocytes, Platelets (PLT), neutrophil-to-lymphocyte ratio (NLR)
Inflammation-related markers are assessed using venous blood samples. WBC and Platelets (PLT) are measured in 10\^9/L. Neutrophils, lymphocytes, and Monocytes are reported as percentages (%). CRP is measured in mg/dL. The neutrophil-to-lymphocyte ratio (NLR) is reported as a unitless ratio.
Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery
Inflammation Markers 3: Procalcitonin, Blood Culture (BC), Serum Amyloid A (SAA), Zonulin, Cytokine (TNF-α, IFN-γ, IL-2, IL-6, IL-10, IL-12, IL-17)
Procalcitonin, BC, SAA, Zonulin, Cytokine (TNF-α, IFN-γ, IL-2, IL-6, IL-10, IL-12, IL-17) are assessed using venous blood samples. Procalcitonin is measured in ng/mL, SAA in mg/L, and Zonulin in ng/mL. BC is recorded as a qualitative result (Positive/Negative). Cytokines assessed include TNF-α, IFN-γ, IL-2, IL-6, IL-10, IL-12, and IL-17, measured in pg/mL.
Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery
Immune-related Markers 1: Natural Killer cell cytotoxicity (NK cytotoxicity), Natural Killer cell subset (NK subset)
Immune-related markers are assessed using venous blood samples. NK cytotoxicity and NK subset are reported as percentages (%).
Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30)
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) is used to assess quality of life in patients with cancer. It consists of three domains: global health status/quality of life, functional, and symptom domains, with a total of 30 items. Scores are transformed to a scale ranging from 0 to 100 according to the EORTC QLQ-C30 scoring manual. Higher scores for global health status/quality of life and the functional domain indicate better quality of life, whereas higher scores for the symptom domain indicate worse quality of life.
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Bowel Function Assessment 1: Bowel Diary
As part of the bowel function assessment, a bowel diary is used to record the frequency and form of bowel movements.
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Bowel Function Assessment 2: Postoperative Bowel Function Questionnaire
As part of the bowel function assessment, the Postoperative Bowel Function Questionnaire is used to assess postoperative bowel function and recovery, including time to first passage of flatus, time to first bowel movement, and other related measures.
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Nutritional Status Assessment 1: Patient-Generated Subjective Global Assessment (PG-SGA)
As part of the nutritional status assessment, the Patient-Generated Subjective Global Assessment (PG-SGA) is used to evaluate nutritional status based on factors including changes in body weight and dietary intake, gastrointestinal symptoms affecting food intake, physical examination findings, and comorbidities.
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Nutritional Status Assessment 2: Prognostic Nutritional Index (PNI)
As part of the nutritional status assessment, the Prognostic Nutritional Index (PNI) is calculated based on Serum Albumin and Total Lymphocyte Count. PNI is calculated as 10 × Serum Albumin (g/dL) + 0.005 × Total Lymphocyte Count (/mm³).
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Fecal Microbiome (16S/Shotgun, NGS, SCFA)
Fecal collection kits are sent to participants, who are instructed to collect stool samples at home within 2 days of each visit. The collected samples are placed in the designated kits and returned by courier to the analytical laboratory.
Time frame: 1 week before surgery, 4 weeks, 12 weeks after surgery
Tumor Transcriptome (RNA-seq)
Normal tissue and tumor tissue are collected during surgery.
Time frame: During surgery
Adaptive immunity test (T cell exhaustion marker, CEA/NY-ESO-1/ST4-specific T cell)
Adaptive immunity is assessed using T-cell exhaustion markers and CEA/NY-ESO-1/ST4-specific T-cell responses. These measurements are used to analyze the association between changes in immune status before and after surgery and clinical prognosis, and to evaluate changes in immune response following probiotic intake.
Time frame: Baseline, 4 weeks, 12 weeks after surgery
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.